Cetraxate is an oral gastrointestinal medication which has a cytoprotective effect. Double-blind clinical trials in patients with gastric ulcer compared the effects of cetraxate with those of the drug gefarnate, a common standard drug treatment for gastric ulcer.

Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors and used in the treatment of dry mouth associated with sjogren’s syndrome.

Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors and used in the treatment of dry mouth associated with sjogren’s syndrome.

Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors and used in the treatment of dry mouth associated with sjogren’s syndrome.

Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors and used in the treatment of dry mouth associated with sjogren’s syndrome.

CGP 52411 inhibited the EGF-R protein-tyrosine kinase in vitro with high selectivity. In cells, CGP52411 selectively inhibited both ligand-induced EGF-R and p185c-erbB2 autophosphorylation and c-fos mRNA induction.

CGP 52411 inhibited the EGF-R protein-tyrosine kinase in vitro with high selectivity. In cells, CGP52411 selectively inhibited both ligand-induced EGF-R and p185c-erbB2 autophosphorylation and c-fos mRNA induction.

CGP 52411 inhibited the EGF-R protein-tyrosine kinase in vitro with high selectivity. In cells, CGP52411 selectively inhibited both ligand-induced EGF-R and p185c-erbB2 autophosphorylation and c-fos mRNA induction.

CGP 52411 inhibited the EGF-R protein-tyrosine kinase in vitro with high selectivity. In cells, CGP52411 selectively inhibited both ligand-induced EGF-R and p185c-erbB2 autophosphorylation and c-fos mRNA induction.

CGP 52411 inhibited the EGF-R protein-tyrosine kinase in vitro with high selectivity. In cells, CGP52411 selectively inhibited both ligand-induced EGF-R and p185c-erbB2 autophosphorylation and c-fos mRNA induction.

CGP 20712 is a highly selective and potent β1-adrenoceptor antagonist (IC50 = 0.7 nM). Displays 10,000-fold selectivity over β2-adrenoceptors.

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics relative to ATP.

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics relative to ATP.

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics relative to ATP.

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics relative to ATP.

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics relative to ATP.

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics relative to ATP.

CGS 15435, a potent thromboxane (TxA2) synthetase inhibitor with an IC50 of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI2 synthetase and lipoxygenase enzymes.

CGS 15435, a potent thromboxane (TxA2) synthetase inhibitor with an IC50 of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI2 synthetase and lipoxygenase enzymes.

CGS 15435, a potent thromboxane (TxA2) synthetase inhibitor with an IC50 of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI2 synthetase and lipoxygenase enzymes.